$17.76
4.44% yesterday
Nasdaq, May 20, 09:48 pm CET
ISIN
US6412881053
Symbol
NPCE

NeuroPace Inc Stock News

Neutral
Seeking Alpha
7 days ago
NeuroPace, Inc. (NASDAQ:NPCE ) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Jeremy Feffer - LifeSci Advisors Joel Becker - Chief Executive Officer Rebecca Kuhn - Chief Financial Officer Conference Call Participants Mike Kratky - Leerink Partners Nelson Cox - Lake Street Ross Osborn - Cantor Fitzgerald Priya Sachdev - UBS Rohin Patel - JPMorgan Michael Polark - W...
Neutral
GlobeNewsWire
8 days ago
-- Reported record quarterly revenue of $22.5 million in Q1 2025, driven by increasing market demand for core RNS System products -- -- Increased full-year 2025 revenue guidance to $93 to $97 million -- -- On track to announce topline data from the NAUTILUS pivotal study in the second half of 2025 -- -- Management scheduled to host a conference call today at 4:30 p.m. ET -- MOUNTAIN VIEW, Calif.
Neutral
GlobeNewsWire
about one month ago
-- Minimal expected impact to operations and financial results -- -- Company to report first quarter 2025 financial results on May 13, 2025 --
Neutral
GlobeNewsWire
about one month ago
Three-year data from the largest FDA-reviewed prospective neuromodulation study of safety and effectiveness in drug-resistant focal epilepsy1 Long-term seizure reduction with a median reduction of 82% at 3 years. Seizure freedom with 42% of patients remaining seizure free for 6+ months.i MOUNTAIN VIEW, Calif.
Neutral
GlobeNewsWire
about 2 months ago
MOUNTAIN VIEW, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, will be attending and presenting at the upcoming American Academy of Neurology (AAN) 2025 Annual Meeting, which is being held in San Diego from April 5 – 9.
Neutral
GlobeNewsWire
about 2 months ago
-- Beginning of Wind Down of Stereo EEG (SEEG) Distribution Relationship in Q4 2025 -- -- Maintaining 2025 Revenue Guidance -- -- No Change to Long-Range Plan Expectations of Cash Flow Breakeven by the end of 2027 and Achievement of 20%+ Revenue CAGR -- MOUNTAIN VIEW, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the ...
Neutral
GlobeNewsWire
about 2 months ago
MOUNTAIN VIEW, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 24th Annual Needham Virtual Healthcare Conference at 3:00pm ET (12:00pm PT) on Tuesday, April 8, 2025.
Neutral
Seeking Alpha
3 months ago
NeuroPace, Inc. (NASDAQ:NPCE ) Q4 2024 Earnings Conference Call March 4, 2025 4:30 PM ET Company Participants Jeremy Feffer - Investor Relations Joel Becker - Chief Executive Officer and Board Member Rebecca Kuhn - Chief Financial Officer, Vice President, Finance and Administration Conference Call Participants Priya Sachdeva - UBS Rohin Patel - JP Morgan Frank Takkinen - Lake Street Capital Mar...

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today